Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|January 22, 2020
Bio-Techne, Fresenius Kabi, Wilson Wolf Form Joint Venture for Cell and Gene Therapy
Author(s)Pharmaceutical Technology Editors
The new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise.
Advertisement
Bio-Techne, Fresenius Kabi, and Wilson Wolf announced on Jan. 21, 2020 that they are forming a new joint venture company focused on supporting researchers and biopharmaceutical companies in the field of cell and gene therapy. The venture has yet to be named.
According to a Bio-Techne press release, the new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise. Wilson Wolf will supply the company with its G-Rex technology, platform designed to increase the quantity and quality of immune cells for personalized cell therapies; Bio-Techne will offer up its range of proteins, reagents, media, and gene-editing technologies; and Fresenius Kabi will provide its Lovo cell processing system, which washes, concentrates, and harvests cells at a scale needed to develop and commercialize cell and gene therapies.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement